Day: November 5, 2024

Knoxville, Tennessee, Nov. 05, 2024 (GLOBE NEWSWIRE) — Healthcare Integrated Technologies, Inc. (HiTC), a leader in AI-driven healthcare solutions, is pleased to announce the appointment of Caleb Dixon as Chief Customer Officer (CCO). Mr. Dixon brings over 24 years of experience in healthcare innovation, technology modernization, and operational leadership. Throughout his career, Mr. Dixon has excelled in modernizing technology for physician practices, developing data and analytics tools, deploying EMR/HIE/Portal solutions, and building effective operations teams for health systems and software development studios. His recent roles include Founder & CEO of Socket Health and Senior Vice President of Innovation at SwitchPoint Ventures. Scott Boruff, CEO of HiTC, stated, “We are thrilled to welcome Caleb to our executive...

All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT with reduced intensity conditioning Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10, at 8:00 a.m. ET WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that preliminary results from the ALLOHA™ Phase 1 trial of TSC-100 and TSC-101, in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and...

Basel, 05 November 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held 7-10 December 2024 in San Diego, US. The data underscore Roche’s commitment to advance patient outcomes in lymphoma with long-term follow-up of its approved medicines Polivy® (polatuzumab vedotin), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab) as well as new investigational combination data. Key presentations include:Five-year data from the phase III POLARIX study (abstract #469) reinforce the potential of Polivy in combination with MabThera®/Rituxan® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) to provide durable and lasting remissions and for the first time show a positive...

ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product Ongoing Phase 1 Data Supported the FDA’s Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC TherapiesSOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma MRD data to be featured in oral presentation at the 66th Annual American Society of Hematology (ASH) Annual Meeting SOMERSET, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will present new data on minimal residual disease (MRD) negativity rates from the Phase 3 CARTITUDE-4 trial in multiple myeloma patients treated with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus standard of care (SoC). The study evaluated lenalidomide-refractory patients who have received one to three prior lines of therapy and will be featured in an oral presentation...

– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th – – Ziftomenib combined with ven/aza in R/R NPM1-m or KMT2A-r AML patients selected for poster presentation on Sunday, December 8th – SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that two abstracts highlighting clinical data from the KOMET-007 combination trial of ziftomenib, the Company’s potent and selective menin inhibitor, have been accepted for presentation at the upcoming American Society of Hematology (ASH) Annual Meeting, to be held in San Diego from December 7-10, 2024. KOMET-007 is a multicenter Phase 1 trial...

– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in Lower-risk Myelodysplastic Syndromes will be Presented and Published – – Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted Onsite on Monday, December 9 – CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on mitapivat and tebapivat (AG-946), the company’s PK activators, will be featured in oral and poster presentations during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition...

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) — LPL Financial LLC (Nasdaq: LPLA), announced today that financial advisor Michael Bernier, CFP®, AIF®, has joined LPL’s employee advisor channel, Linsco by LPL Financial, to launch GWC Financial Advisors. He reported serving approximately $165 million in advisory, brokerage and retirement plan assets* and joins LPL from Canter Wealth. He will operate from the Linsco office in San Diego. With more than 20 years of experience in wealth management, Bernier helps clients work toward their goals using meticulous financial planning. His deep understanding of personal finance enables him to develop strategic approaches in the areas of tax strategy, investment management and retirement and estate planning. “There are many things to worry about in life, but I get joy in taking at least one thing...